药捷安康-B(02617)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02617 药捷安康-B

未开盘 06-05 16:09:12

31.580

-2.400

-7.06%

最高35.560	最低31.580	成交量253.40万
今开34.300	昨收33.980	日振幅11.71%
总市值128.85亿	流通市值98.85亿	总股本4.08亿
成交额8,553万	换手率0.81%	流通股本3.13亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02617","market":"HK","secType":"STK","nameCN":"药捷安康-B","latestPrice":31.58,"timestamp":1780646952005,"preClose":33.98,"halted":0,"volume":2534000,"delay":0,"changeRate":-0.07062978222483811,"floatShares":313000000,"shares":408000000,"eps":-0.76,"marketStatus":"未开盘","change":-2.4,"latestTime":"06-05 16:09:12","open":34.3,"high":35.56,"low":31.58,"amount":85527050,"amplitude":0.117128,"askPrice":31.86,"askSize":7500,"bidPrice":31.58,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":-0.803,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1780882200000},"marketStatusCode":0,"adr":0,"listingDate":1750608000000,"exchange":"SEHK","adjPreClose":33.98,"openAndCloseTimeList":[[1780623000000,1780632000000],[1780635600000,1780646400000]],"volumeRatio":1.5898430736792406,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02617","defaultTab":"news","newsList":[{"id":"1142196069","title":"异动解读｜药捷安康-B盘中下跌5.41%，ASCO大会公布核心产品临床数据后股价承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1142196069","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142196069?lang=zh_cn&edition=full","pubTime":"2026-06-05 15:20","pubTimestamp":1780644021,"startTime":"0","endTime":"0","summary":"6月5日，药捷安康-B盘中下跌5.41%，报32.14港元，成交额7285.01万港元。消息面上，公司近日在ASCO大会以壁报形式公布了核心产品替恩戈替尼单药治疗既往FGFR抑制剂经治的晚期胆管癌患者关键II期临床数据，截至数据截止日共50例患者入组。此外，公司此前已获纳入香港交易所科技100指数，将于6月15日起生效。药捷安康是一家专注于肿瘤、炎症及心脏代谢疾病小分子创新疗法的生物制药公司，核心产品替恩戈替尼为处于注册临床阶段的MTK抑制剂。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174158425","title":"药捷安康-B更新5月股份变动月报：H股增发3,836,000股","url":"https://stock-news.laohu8.com/highlight/detail?id=1174158425","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174158425?lang=zh_cn&edition=full","pubTime":"2026-06-02 18:43","pubTimestamp":1780396998,"startTime":"0","endTime":"0","summary":"药捷安康(南京)科技股份有限公司于2026年6月2日发布了截至2026年5月31日的股份变动月报表，披露了公司在2026年5月的股本变动情况。其中，普通股H股由2026年4月底的308,851,673股增加至312,687,673股，增发数量为3,836,000股。根据公告，本月公司完成了以每股港币40.83元的价格配售（或认购）新H股3,836,000股。截至本月末，公司股本总数较上月有所增加，最新已发行股份总数为312,687,673股H股和95,230,960股非上市普通股，合计407,918,633股。据公告内容，月报由联席公司秘书黄荻代表签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639253600","title":"药捷安康-B(02617)：在2026年美国临床肿瘤学会(ASCO)公布替恩戈替尼单药治疗晚期胆管癌关键II期临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2639253600","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639253600?lang=zh_cn&edition=full","pubTime":"2026-05-31 18:08","pubTimestamp":1780222112,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药捷安康-B 发布公告，公司在芝加哥举办的2026年美国临床肿瘤学会上以壁报形式公布了核心产品替恩戈替尼单药治疗既往FGFR抑制剂经治的中国晚期胆管癌患者的最新研究成果。本次ASCO大会上，公开了替恩戈替尼在携带FGFR2变异、既往接受过一种FGFR抑制剂治疗后发生疾病进展的胆管癌患者中的疗效与安全性数据。截至2025年12月27日，共有50例晚期胆管癌患者入组并接受了替恩戈替尼单药治疗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448180.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"药捷安康-B(02617)：在2026年美国临床肿瘤学会(ASCO)公布替恩戈替尼单药治疗晚期胆管癌关键II期临床数据","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639243666","title":"香港交易所科技100指数半年度调整：调入滴普科技(01384)等7只科技股 剔除7只成分股","url":"https://stock-news.laohu8.com/highlight/detail?id=2639243666","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639243666?lang=zh_cn&edition=full","pubTime":"2026-05-29 19:06","pubTimestamp":1780052772,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，5月29日，香港交易所宣布，宣布香港交易所科技100指数的半年度指数调整结果，调入滴普科技(01384)、汇聚科技(01729)、禾赛科技(02525)、极智嘉(02590)、药捷安康(02617)、曹操出行(02643)、长飞光纤光缆(06869)等7只科技股，同时剔除7只成分股。成分股调整将于2026年6月12日(星期五)收市后实施，并于2026年6月15日(星期一)起生效。香港交易所科技100指数是一只宽基指数，追踪100只在香港上市且可在港股通下交易的科技股表现。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a30e0f64b55cbf529d0ed9ec021e9e96","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447901.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1044874839.SGD","BK1255","LU0072462343.USD","LU1242518931.SGD","SG9999006597.SGD","LU0797268264.HKD","LU0348814723.USD","LU0196878994.USD","LU0577902611.USD","00388","LU1993786604.SGD","IE00BZ08YT58.USD","LU0488056044.USD","LU0456846285.SGD","LU0651946864.USD","LU0873338254.USD","LU0307460666.USD","LU1642822792.SGD","BK1149","LU0084288322.USD","LU0918141887.USD","LU1023057109.AUD","LU0831093199.SGD","01729","LU0164939612.USD","LU1831875114.USD","LU0052750758.USD","HK0000151867.HKD","LU0819123356.HKD","LU0274383008.USD","SG9999002562.SGD","LU0149534421.HKD","LU0261947096.USD","LU0784639295.USD","LU0043850808.USD","LU0955648018.USD","LU2449936058.SGD","LU0561508036.HKD","LU0348827113.USD","LU0117841782.USD","LU1048596156.SGD","02525","LU1734074674.USD","LU1282649810.SGD","LU0348735423.USD","BK1506","LU0791591158.USD","BK1117","SG9999001051.SGD","HK0000107257.USD","IE00B3T34201.USD","LU0607220059.USD","LU0117844026.USD","LU2257852520.SGD","SG9999004220.SGD","IE00BZ08YR35.GBP","LU0594300419.USD","LU0577902298.EUR","LU1366334651.USD","LU0011963245.USD","LU1504937902.USD","LU1282649067.USD","LU0979878070.USD","LU2226246903.HKD","LU0762542818.HKD","LU0898667661.SGD","LU0516422440.USD","LU1282648689.USD","LU0819121731.USD","LU0651947912.USD","LU1051768304.USD","LU0082770016.USD","LU0594300179.USD","BK1589","LU0061477393.USD","LU0067412154.USD","LU0082770016.SGD","LU0791590937.USD","LU1807302812.USD","SG9999001846.SGD","LU0708995583.HKD","BK1610","LU0856984785.SGD","LU0762541174.USD","LU1981816686.USD","BK1161","LU0197773160.USD","LU0648948544.HKD","IE00BZ08YS42.EUR","LU0577902371.SGD","LU0096374516.USD","LU1044876610.USD","LU0620787316.HKD","LU1044875133.USD","LU0327786744.USD","LU0577902538.SGD","BK1521","LU0650527681.SGD","LU0359202008.SGD","LU0384037296.USD","LU2039709279.SGD","01384","LU0320764599.SGD","LU0348767384.USD","LU0417516738.SGD","LU0314109678.HKD","LU0831103253.SGD","02590","02617","LU0955669360.SGD","LU0516423174.USD","80388","SGXZ90724238.SGD","LU1328277881.USD","LU0918141705.HKD","LU0348825331.USD","LU1051769294.HKD","LU0501845795.SGD","LU0540923850.HKD","IE0003795394.USD","LU0886674414.USD","LU0516423091.SGD","LU0169518387.USD","LU1813983027.USD","SG9999001093.SGD","SG9999002463.SGD","LU0048597586.USD","BK1523","LU0577902454.USD","LU1211504680.USD","LU1048588211.SGD","LU0251144936.SGD","LU0605514214.HKD","LU0955623706.USD","02643","BK1144","LU0634319403.HKD","LU1226287529.USD","LU0821914370.USD","LU0072913022.USD","LU0370786039.SGD","LU0630378429.USD","LU1366334578.USD","LU0211977185.USD","BK1131","LU0417516902.SGD","LU0572944931.SGD","LU0516422952.EUR","BK1183","LU0140636845.USD","IE0003851619.USD","LU0630378692.HKD","LU1282649141.HKD","LU0197773673.USD","HKXCY","601869","BK1116","LU0165289439.USD","LU1515016050.SGD","LU1481107354.HKD","LU0149721374.USD","LU0762540952.USD","LU0048580855.USD","HSAI","LU0588546209.SGD","LU1105468828.SGD","LU1242518857.USD","06869","LU0210527791.USD","LU1130305938.SGD","LU0348816934.USD","LU0359201885.HKD","LU1655091459.SGD","IE00BKZH1Z71.USD","LU0359201612.USD","LU0106959298.USD","LU0516422366.SGD","LU0164880469.USD","LU0348766576.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143184711","title":"药捷安康-B：配售3,836,000股H股，涉资约1.57亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1143184711","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143184711?lang=zh_cn&edition=full","pubTime":"2026-05-27 21:02","pubTimestamp":1779886929,"startTime":"0","endTime":"0","summary":"药捷安康-B（股票代码：02617）于2026年5月27日发布公告，宣布通过配售方式发行3,836,000股H股。该次发行基于公司于2025年8月4日召开的股东周年大会授权。\n本次配售股份占发行前公司已发行股本约1.24%，每股价格为港币40.83元，合计涉资约1.57亿港元。配售完成后，公司已发行股本由308,851,673股增至312,687,673股，库存股数量维持为零。\n公司同时在公告中确认，已遵守香港联合交易所有限公司证券上市规则及相关法律法规，并按照董事会的正式授权推进各项程序。公告由董事长兼首席执行官吴永谦先生签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"药捷安康-B：配售3,836,000股H股，涉资约1.57亿港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638225688","title":"药捷安康-B(02617)完成发行合共383.6万股配售股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2638225688","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638225688?lang=zh_cn&edition=full","pubTime":"2026-05-27 20:55","pubTimestamp":1779886557,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药捷安康-B(02617)发布公告，配售协议所载所有条件均已达成，有关配售事项已于2026年5月27日完成。配售代理已成功以每股配售股份40.83港元的配售价向不少于六名承配人配售合共383.6万股配售股份。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446841.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638522903","title":"港股异动 | 药捷安康-B(02617)高开逾8% 替恩戈替尼联合新型内分泌治疗经治后进展的mCRPC II期临床获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2638522903","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638522903?lang=zh_cn&edition=full","pubTime":"2026-05-27 09:24","pubTimestamp":1779845079,"startTime":"0","endTime":"0","summary":"消息面上，5月26日，药捷安康-B发布公告，公司核心产品替恩戈替尼联合新型内分泌治疗用于经治后进展的转移性去势抵抗性前列腺癌的II期临床试验，已于2026年5月25日获国家药品监督管理局批准。替恩戈替尼单一疗法已在既往接受过多线治疗的mCRPC患者显出令人鼓舞的抗肿瘤疗效。此外，替恩戈替尼单药治疗mCRPC已于2025年6月获得美国FDA的快速通道认证。替恩戈替尼是全球首个且唯一一个同时抑制FGFR/JAK通路，并针对mCRPC有临床疗效证据的研究药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446385.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK4588","02617","BK1161","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638136510","title":"药捷安康-B(02617)：替恩戈替尼联合新型内分泌治疗用于经治后进展的转移性去势抵抗性前列腺癌中国II期临床试验获批开展","url":"https://stock-news.laohu8.com/highlight/detail?id=2638136510","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638136510?lang=zh_cn&edition=full","pubTime":"2026-05-26 21:39","pubTimestamp":1779802769,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药捷安康-B 公布，公司核心产品替恩戈替尼联合新型内分泌治疗用于经治后进展的转移性去势抵抗性前列腺癌 的II期临床试验，已于2026年5月25日获国家药品监督管理局批准。本试验为一项评价替恩戈替尼联合NHT用于经治后进展的mCRPC患者的安全性、疗效及药代动力学的开放、多中心、II期临床研究。替恩戈替尼单一疗法已在既往接受过多线治疗的mCRPC患者显出令人鼓舞的抗肿瘤疗效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446258.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102727570","title":"药捷安康将启动TT-973-MS联合伏美替尼治疗晚期非小细胞肺癌的II期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1102727570","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102727570?lang=zh_cn&edition=full","pubTime":"2026-05-26 21:31","pubTimestamp":1779802313,"startTime":"0","endTime":"0","summary":"药捷安康（南京）股份有限公司宣布，计划开展一项针对晚期非小细胞肺癌（NSCLC）的II期临床试验，该试验将评估其候选药物TT-973-MS与伏美替尼（Firmonertinib）联合疗法的安全性与有效性。这一举措标志着公司在该治疗领域研发进程的重要推进，旨在探索新的联合治疗方案，为患者提供更多潜在的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638510519","title":"药捷安康-B(02617)与艾力斯达成临床合作及供药协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2638510519","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638510519?lang=zh_cn&edition=full","pubTime":"2026-05-26 21:30","pubTimestamp":1779802215,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药捷安康-B 公布，公司与上海艾力斯医药科技股份有限公司(艾力斯)达成临床合作及供药协议。根据协议条款，药捷安康作为本临床试验的申办方，承担本临床试验的运营与费用。艾力斯免费提供本临床试验所需要的甲磺酸伏美替尼片。截至2025年12月31日，公司已完成 I期临床试验，TT-00973耐受性良好，并在部分的实体肿瘤患者中观察到临床疗效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446253.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","688578","02617","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134689741","title":"药捷安康与上海艾力斯特宣布就非小细胞肺癌临床试验达成合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1134689741","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1134689741?lang=zh_cn&edition=full","pubTime":"2026-05-26 21:29","pubTimestamp":1779802156,"startTime":"0","endTime":"0","summary":"药捷安康（南京）股份有限公司与上海艾力斯特医药科技有限公司近日共同宣布，双方已就一项针对非小细胞肺癌（NSCLC）的临床试验达成战略合作。此次合作旨在整合双方在创新药物研发领域的专业优势，加速推进相关疗法的临床验证进程，以期惠及广大患者。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636889352","title":"零售药店个账管理设置白名单；药捷安康拟折让18%配售H股","url":"https://stock-news.laohu8.com/highlight/detail?id=2636889352","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636889352?lang=zh_cn&edition=full","pubTime":"2026-05-20 08:01","pubTimestamp":1779235287,"startTime":"0","endTime":"0","summary":"政策动向零售药店个账管理设置白名单国家医保局办公室、财政部办公厅5月19日发布《关于进一步加强定点零售药店职工基本医疗保险个人账户使用监督管理的通知》，明确建立定点零售药店职工医保个人账户支付白名单制度，白名单内的，个人账户在定点零售药店可以支付；白名单外的，不予支付。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605203742645294.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605203742645294.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636891168","title":"港股异动 | 药捷安康-B (02617) 现跌超3% 拟折让约18%配股净筹1.52亿港元 年内第三次配股集资","url":"https://stock-news.laohu8.com/highlight/detail?id=2636891168","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636891168?lang=zh_cn&edition=full","pubTime":"2026-05-19 11:17","pubTimestamp":1779160655,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，药捷安康-B 今早股价剧烈波动，盘中低见45.24港元一度跌逾9%，随后强势反弹至53.8港元，现股价再度走低。截至发稿，跌3.14%，报48.24港元，成交额1.29亿港元。消息面上，药捷安康今早公布，拟向不少于六名承配人配售383.6万股新股，占扩大后约0.94%，每股配售价40.83港元，较5月18日收市价49.8港元折让约18.01%。假设配售股份获悉数配售，所得款项总额约1.57亿港元，净额约1.52亿港元。值得注意的是，药捷安康此次配股是2026年内第三次进行配股集资。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1443297.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","VXUS","BK1161","BK4585","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636889414","title":"港股速报 | 恒指小幅高开 百度迎利好 阿里早盘涨超2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636889414","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636889414?lang=zh_cn&edition=full","pubTime":"2026-05-19 11:12","pubTimestamp":1779160358,"startTime":"0","endTime":"0","summary":"5月19日，港股市场表现平稳，恒指早盘小幅高开。恒生指数开盘报25693.37点，上涨18.19点，涨幅0.07%；恒生科技指数开盘报4838.36点，下跌6.58点，跌幅0.14%。焦点公司方面，百度集团-SW（HK09888）迎来利好，早盘涨超2%。消息面，百度集团发布2026年第一季度财报。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605193741723547.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605193741723547.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0979878070.USD","BABX","BK4602","BK4614","LU1688375341.USD","BK4565","IE00BF5LJ272.USD","LU1769817096.USD","BK4122","LU0310800965.SGD","BK4534","LU1046422090.SGD","07300","LU0328353924.USD","83115","IE00B0JY6N72.USD","LU1003077747.HKD","LU1008478684.HKD","LU1152091168.USD","BK4533","BK4581","BK4514","LU0287142896.SGD","LU1048588211.SGD","02833","LU0128525689.USD","BIDG","LU0553294199.USD","LU1282648689.USD","LU1769817179.HKD","LU0072462343.USD","03419","BK4535","LU1048596156.SGD","LU1823568750.SGD","LU0880133367.SGD","LU0359202008.SGD","LU1105468828.SGD","LU0545039389.USD","LU0501845795.SGD","BK4612","LU1880383366.USD","82800","BIDU","LU0918141887.USD","LU1242518857.USD","BK4579","BK4554","LU0949170772.SGD","07500","BK4585","LU1515016050.SGD","LU1051769294.HKD","BK4558","LU1152091754.HKD","LU1115378108.SGD","BABU","BK4543","BK4607","LU0072913022.USD","BK4538","BK4527","HSTECH","LU1051768304.USD","09988","LU0640798160.USD","BK4505","02800","LU0738911758.USD","LU1267930227.SGD","BK4504","LU0918141705.HKD","BK4526","02617","BK4220","LU0348814723.USD","513600","LU0456842615.SGD","LU0173614495.USD","LU2226246903.HKD","MHImain","LU0251143458.SGD","07200","MCHmain","LU1046421795.USD","BK4552","BK4077","LU1235294995.USD","BABW","03037","BK4502","BK4531","LU0651946864.USD","ALBmain","LU0348816934.USD","LU0359201612.USD","BBYY","BK4548","LU0661504455.SGD","BK4524","HHImain","BK4574","BK4587","03115","KBAB","BABA","BK4588","BABO","IE00BFMHRM44.USD","LU0651947912.USD","LU0052756011.USD","LU0047713382.USD","KBDU","LU1242518931.SGD","LU2148611432.USD","BK4503","LU0106959298.USD","09115","LU0067412154.USD","LU1023057109.AUD","LU0797268264.HKD","HSI","LU0821914370.USD","BK4575","09888"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151064397","title":"异动解读 | 药捷安康-B盘中大涨6.12%，市场看好其配售筹资用于核心产品开发","url":"https://stock-news.laohu8.com/highlight/detail?id=1151064397","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151064397?lang=zh_cn&edition=full","pubTime":"2026-05-19 10:49","pubTimestamp":1779158954,"startTime":"0","endTime":"0","summary":"药捷安康-B（02617）今日盘中股价大幅上涨6.12%，引起了投资者的关注。消息面上，公司于交易时段前发布公告，宣布与配售代理订立配售协议，计划以每股40.83港元的价格配售约383.6万股H股，预计所得款项净额约为1.52亿港元。公司表示，此次配售所得款项净额的约90%将用于其核心产品Tinengotinib新适应症的开发，其余约10%用于营运资金及一般企业用途。市场分析认为，尽管配售价格较前一日收盘价有所折让，但资金将主要用于核心在研药物的临床开发，这增强了投资者对公司未来研发管线推进及长期增长潜力的信心，从而推动了股价的积极表现。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187670148","title":"异动解读 | 药捷安康-B盘中大跌5.22%，因折让约18%配股筹资","url":"https://stock-news.laohu8.com/highlight/detail?id=1187670148","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1187670148?lang=zh_cn&edition=full","pubTime":"2026-05-19 09:36","pubTimestamp":1779154600,"startTime":"0","endTime":"0","summary":"药捷安康-B今日盘中大跌5.22%，引起了市场的广泛关注。消息面上，公司于交易时段前宣布，拟以每股40.83港元的价格配售383.6万股新H股，配售价较前一交易日收盘价折让约18.01%，预计净筹资约1.52亿港元。折价配售新股通常会对二级市场股价造成短期压力，因稀释效应及较低的配售价可能影响投资者信心。根据公告，此次配售所得款项净额约90%将用于公司核心产品Tinengotinib新适应症的开发，其余10%用于营运资金及一般企业用途。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636002819","title":"药捷安康-B(02617)拟折让约18.01%配售383.6万股 净筹1.52亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2636002819","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636002819?lang=zh_cn&edition=full","pubTime":"2026-05-19 06:37","pubTimestamp":1779143838,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药捷安康-B 发布公告，于2026年5月19日，本公司与配售代理订立配售协议，据此，配售代理有条件同意作为本公司的配售代理，按尽力基准促使承配人按每股配售股份40.83港元的配售价购买383.6万股配售股份。预期配售代理将促使不少于六名承配人认购配售股份。配售股份的承配人须由配售代理根据上市规则的要求厘定。假设所有配售股份获悉数配售及待完成后，预期配售事项所得款项总额及所得款项净额将分别约为 1.57亿港元及1.52亿港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1443197.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"药捷安康-B(02617)拟折让约18.01%配售383.6万股 净筹1.52亿港元","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183160539","title":"药捷安康-B预计全球发售所得款项总额约1.566亿港元，净额约1.521亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1183160539","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183160539?lang=zh_cn&edition=full","pubTime":"2026-05-19 06:32","pubTimestamp":1779143536,"startTime":"0","endTime":"0","summary":"药捷安康-B（股票代码：02617）全球发售的预计所得款项总额及净额已公布。根据相关数据，本次发售的所得款项总额预计约为1.5662亿港元。扣除各项包销费用、佣金及其他相关开支后，公司预计将获得的净所得款项约为1.5213亿港元。\n此次资金募集旨在支持公司的研发活动、业务拓展及一般营运资本需求。所得款项的运用将遵循公司既定的发展战略，以推动其核心管线产品的开发进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636947580","title":"药捷安康-B(02617)在自然杂志子刊发表核心产品替恩戈替尼单药及联合阿替利珠单抗治疗晚期实体瘤的探索性临床结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2636947580","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636947580?lang=zh_cn&edition=full","pubTime":"2026-05-17 18:44","pubTimestamp":1779014647,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药捷安康-B 发布公告，在Nature Communications发表核心产品替恩戈替尼单药及联合阿替利珠单抗治疗晚期实体瘤的探索性临床结果。替恩戈替尼单药治疗A组的客观缓解率达到为16.7%，联合阿替利珠单抗用药B组的客观缓解率为22.6%，均展现出抗肿瘤活性。对于既往经FGFR抑制剂治疗后进展、携带FGFR2融合突变的胆管癌患者，替恩戈替尼单药治疗客观缓解率达66.7%。上述研究结果支持进一步推进替恩戈替尼单药及联合免疫疗法的临床开发。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1442634.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160900405","title":"药捷安康-B更新4月股份变动月报表，总股本增至404,082,633股","url":"https://stock-news.laohu8.com/highlight/detail?id=1160900405","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160900405?lang=zh_cn&edition=full","pubTime":"2026-05-06 19:26","pubTimestamp":1778066760,"startTime":"0","endTime":"0","summary":"药捷安康 (南京)科技股份有限公司（股票代码：02617）于2026年5月6日披露了截至2026年4月30日的证券变动月报表。报告显示，公司H股本月由303,766,673股增至308,851,673股，较上月增加5,085,000股；非上市股份维持在95,230,960股不变。公司法定/注册股本因此增至404,082,633股。\n本月内，公司无股份购回、注销或库藏股变动，也无新的股份期权或其他股权激励计划的相关变动信息。公司于公告中确认，其已遵守香港联合交易所有限公司《上市规则》及其他适用的法律法规。公告由公司联席公司秘书黄荻签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.transtherabio.com","stockEarnings":[{"period":"1week","weight":-0.0982},{"period":"1month","weight":-0.3497},{"period":"3month","weight":-0.6567},{"period":"6month","weight":-0.8355},{"period":"1year","weight":1.4015},{"period":"ytd","weight":-0.7252}],"compareEarnings":[{"period":"1week","weight":-0.0088},{"period":"1month","weight":-0.0478},{"period":"3month","weight":-0.0309},{"period":"6month","weight":-0.0431},{"period":"1year","weight":0.0441},{"period":"ytd","weight":-0.0261}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"药捷安康（南京）科技股份有限公司是一家从事生物制药的中国公司，主要专注于发现及开发肿瘤、炎症及心脏代谢疾病小分子创新疗法。该公司的核心产品Tinengotinib是一种处于注册临床阶段的内部发现和开发的MTK抑制剂，适用于某些复发或难治的耐药实体瘤。该公司的肿瘤产品线包括TT-00973（针对 AXL）、TT-01488（用于血液系统恶性肿瘤）、TT-01688（用于炎症性疾病）和 TT-00920（用于慢性心力衰竭）。这些产品能够对多种癌症类型（包括前列腺癌、肝癌、乳腺癌和BTC）产生疗效。它还可用于治疗肝细胞癌、乳腺癌、胆道癌和Pan-FGFR实体瘤。","exchange":"SEHK","name":"药捷安康-B","nameEN":"TRANSTHERA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"药捷安康-B(02617)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供药捷安康-B(02617)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"药捷安康-B,02617,药捷安康-B股票,药捷安康-B股票老虎,药捷安康-B股票老虎国际,药捷安康-B行情,药捷安康-B股票行情,药捷安康-B股价,药捷安康-B股市,药捷安康-B股票价格,药捷安康-B股票交易,药捷安康-B股票购买,药捷安康-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"药捷安康-B(02617)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供药捷安康-B(02617)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}